BioCentury
ARTICLE | Clinical News

Fovista pegpleranib: Completed Phase III enrollment

June 27, 2016 7:00 AM UTC

Ophthotech completed enrollment of about 622 patients in the last of 3 sham-controlled, double-blind, international Phase III trials evaluating intravitreal injections of 1.5 mg Fovista. The trial is comparing Fovista and intravitreal injections of 2 mg Eylea aflibercept or 1.25 mg Avastin bevacizumab vs. Eylea or Avastin alone. Top-line data from the first 2 trials are expected in 4Q16. ...